Advertisement

Lidocaine Injection

[11 July 2014]

Products Affected - Description

0.4% Lidocaine and 5% Dextrose
0.4% Lidocaine and 5% Dextrose, Hospira
4 mg/mL, 250 mL premixed bag (NDC 00409-7931-32)
4 mg/mL, 500 mL premixed bag (NDC 00409-7931-24)

0.8% Lidocaine and 5% Dextrose
0.8% Lidocaine and 5% Dextrose, Baxter
8 mg/mL, 250 mL premixed bag (NDC 00338-0411-02)

0.8% Lidocaine and 5% Dextrose, Hospira
8 mg/mL, 250 mL premixed bag (NDC 00409-7939-32)

1% Lidocaine 
1% Xylocaine injection, Fresenius Kabi, USA
10 mg/mL, 20 mL vial (NDC 63323-0485-27)

1% Xylocaine - MPF injection, Fresenius Kabi, USA
10 mg/mL, 2 mL vial (NDC 63323-0492-27)
10 mg/mL, 30 mL vial (NDC 63323-0492-37)

1.5% Lidocaine
1.5% Xylocaine - MPF injection, Fresenius Kabi, USA
15 mg/mL, 10 mL ampule (NDC 63323-0493-97


2% Lidocaine

2% Lidocaine injection, Amphastar IMS
20 mg/mL, 5 mL Luer-Jet emergency syringes (NDC 00548-3390-01) - NDC discontinued

2% Lidocaine injection, AuroMedics
20 mg/mL, 2 mL vial (NDC 55150-0164-02)
20 mg/mL, 5 mL vial (NDC 55150-0165-05)
 
2% Xylocaine injection, Fresenius Kabi
20 mg/mL, 50 mL vial (NDC 63323-0486-57)
20 mg/mL, 20 mL vial (NDC 63323-0486-27)

2% Xylocaine - MPF injection, Fresenius Kabi
20 mg/mL, 5 mL vial (NDC 63323-0495-07)

2% Lidocaine injection, Fresenius Kabi, USA
20 mg/mL, 5 mL SD Tear Top vial, preservative-free (NDC 63323-0208-05)

2% Lidocaine injection, Hospira
20 mg/mL, 5 mL vial, preservative-free (NDC 00409-2066-05)

Reason for the Shortage

  • Hospira has lidocaine presentations on shortage due to manufacturing delays.
  • Fresenius Kabi, USA (formerly APP) has Xylocaine and lidocaine presentations on shortage due to increased demand for the product.
  • Amphastar had lidocaine 2% emergency syringes on shortage due to increased demand for the product.
  • BBraun has lidocaine and dextrose premixed bags on shortage due to increased demand for the product.
  • Baxter discontinued two lidocaine and dextrose premixed bag presentations in March, 2012.
  • AuroMedics introduced lidocaine injection in February 2014.

Available Products

0.4% Lidocaine and 5% Dextrose
0.4% Lidocaine and 5% Dextrose, Baxter
4 mg/mL, 500 mL premixed bag (NDC 00338-0409-03)


0.4% Lidocaine and 5% Dextrose, BBraun
4 mg/mL, 250 mL premixed bag (NDC 00264-9594-20)
4 mg/mL, 500 mL premixed bag (NDC 00264-9594-10)

0.5% Lidocaine
0.5% Lidocaine, Hospira
5 mg/mL, 50 mL SD Tear Top Vial, preservative-free (NDC 00409-4278-01)
5 mg/mL, 50 mL SD Flip Top Vial (NDC 00409-4275-01)


0.5% Xylocaine injection, Fresenius Kabi, USA
5 mg/mL, 50 mL vial (NDC 63323-0484-57)

0.5% Xylocaine - MPF injection, Fresenius Kabi, USA
5 mg/mL, 50 mL vial (NDC 63323-0491-57)

0.8% Lidocaine and 5% Dextrose
0.8% Lidocaine and 5% Dextrose, BBraun
8 mg/mL, 250 mL premixed bag (NDC 00264-9598-20)

1% Lidocaine
1% Lidocaine injection, AuroMedics
10 mg/mL, 2 mL ampule (NDC 55150-0158-72)
10 mg/mL, 2 mL ampule (NDC 55150-0158-)
10 mg/mL, 2 mL vial (NDC 55150-0161-02)
10 mg/mL, 30 mL vial (NDC 55150-0163-30)


1% Lidocaine injection, Hospira
10 mg/mL, 50 mL vial (NDC 00409-4276-02)
10 mg/mL, 5 mL preservative-free glass ampule (NDC 00409-4713-02)
10 mg/mL, 20 mL vial (NDC 00409-4276-01)
10 mg/mL, 30 mL preservative-free vial (NDC 00409-4279-02)
10 mg/mL, 30 mL preservative-free vial, sterile pack (NDC 00409-4270-01)
10 mg/mL, 2 mL preservative-free glass ampule (NDC 00409-4713-32)
10 mg/mL, 5 mL LifeShield syringes (NDC 00409-4904-34)
10 mg/mL, 5 mL Ansyr plastic emergency syringes (NDC 00409-9137-05)

1% Lidocaine injection, Fresenius Kabi, USA
10 mg/mL, 10 mL vial (NDC 63323-0201-10)
10 mg/mL, 2 mL vial (NDC 63323-0201-02)

1% Xylocaine - MPF injection, Fresenius Kabi, USA
10 mg/mL, 2 mL glass ampule (NDC 63323-0492-80)
10 mg/mL, 5 mL glass ampule (NDC 63323-0492-89)
10 mg/mL, 5 mL vial (NDC 63323-0492-57)
10 mg/mL, 30 mL vial, sterile pack (NDC 63323-0492-31)

1% Xylocaine injection, Fresenius Kabi, USA
10 mg/mL, 50 mL vial (NDC 63323-0485-57)

1.5% Lidocaine
1.5% Lidocaine injection, Hospira
15 mg/mL, 20 mL ampule, preservative-free (NDC 00409-4776-01)
15 mg/mL, 20 mL sterile pack, glass ampule, preservative-free (NDC 00409-4056-01)


1.5% Xylocaine - MPF injection, Fresenius Kabi, USA
15 mg/mL, 20 mL ampule (NDC 63323-0493-91)


2% Lidocaine
2% Lidocaine injection, Amphastar IMS
20 mg/mL, 5 mL Luer-Jet emergency syringes (NDC 76329-3390-01)


2% Lidocaine injection, AuroMedics
20 mg/mL, 2 mL ampule (NDC 55150-0160-72)

2% Lidocaine injection, Fresenius Kabi, USA
20 mg/mL, 2 mL vial (NDC 63323-0202-02)

2% Xylocaine injection, Fresenius Kabi, USA
20 mg/mL, 10 mL vial (NDC 63323-0486-17)

2% Xylocaine - MPF injection, Fresenius Kabi, USA
20 mg/mL, 2 mL vial (NDC 63323-0495-27)
20 mg/mL, 10 mL ampule (NDC 63323-0496-97)


2% Lidocaine injection, Hospira
20 mg/mL, 2 mL glass ampule, preservative-free (NDC 00409-4282-01)
20 mg/mL, 10 mL glass ampule, preservative-free (NDC 00409-4282-02)
20 mg/mL, 20 mL vial (NDC 00409-4277-01)
20 mg/mL, 50 mL vial (NDC 00409-4277-02)
20 mg/mL, 5 mL Lifeshield glass emergency syringes (NDC 00409-4903-34)
20 mg/mL, 5 mL Ansyr plastic emergency syringes (NDC 00409-1323-05)

4% Lidocaine
4% Xylocaine - MPF injection, Fresenius Kabi, USA
40 mg/mL, 5 mL glass ampule, preservative-free (NDC 63323-0490-89)


4% Lidocaine injection, Hospira
40 mg/mL, 5 mL glass ampule, preservative-free (NDC 00409-4283-01)

Estimated Resupply Dates

Lidocaine 0.4% and Dextrose 5%
  • Hospira has 0.4% lidocaine and 5% dextrose 250 mL and 500 mL bags on back order and the company estimates a release date of 2016.

Lidocaine 0.8% and Dextrose 5%

  • Baxter has 0.8% lidocaine and 5% dextrose 250 mL bags on back order and the company cannot estimate a release date.
  • Hospira has 0.8% lidocaine and 5% dextrose 250 mL bags on back order and the company estimates a release date of 2016.

Lidocaine 0.5%

  • All presentations are available.

Lidocaine 1%

  • Fresenius Kabi has 1% Xylocaine 20 mL vials on back order and the company estimates a release date of mid-August 2014. Check your wholesaler for availability. Fresenius Kabi has 1% Xylocaine MPF 2 mL vials on back order and the company estimates a release date in late-July 2014. Fresenius Kabi has 1% Xylocaine MPF 30 mL vials on back order and the company estimates a release date in mid-July 2014.

Lidocaine 1.5%

  • Fresenius Kabi has 1.5% Xylocaine 10 mL ampules on back order and the company estimates a release date of early-July 2014.

Lidocaine 2%

  • Auromedics has 2% lidocaine 2 mL vials and 5 mL vials on back order and the company estimates a release date in late-July 2014 for the 5 mL vials and early-August 2014 for the 2 mL vials.
  • Fresenius Kabi has 2% Xylocaine 20 mL vials on back order and the company estimates a release date of early-July 2014. Fresenius Kabi has 2% Xylocaine 50 mL vials on back order and the company estimates a release date of late-July 2014. Fresenius Kabi has 2% Xylocaine-MPF 5 mL vials on back order with an estimated release date of mid-July 2014.
  • Fresenius Kabi has 2% lidocaine 5 mL vials on back order until mid-August 2014.
  • Hospira has 2% lidocaine 5 mL vials on back order and the company estimates a release date of July 2014.

Related Shortages

Updated

July 11, 2014; June 30, 2014; June 26, 2014; June 12, 2014; May 22, 2014; May 7, 2014; April 15, 2014; April 7, 2014; March 28, 2014; March 7, 2014; February 24, 2014; February 21, 2014; February 7, 2014; January 9, 2014; December 18, 2013; November 20, 2013; October 17, 2013; September 13, 2013; August 28, 2013; July 25, 2013; June 27, 2013; June 13 2013; May 28, 2013; April 10, 2013; March 13, 2013; February 6, 2013; January 17, 2013; December 12, 2012; October 25, 2012; September 27, 2012; August 22, 2012; August 9, 2012; July 26, 2012; June 21, 2012; June 12, 2012; May 23, 2012; May 2, 2012; April 18, 2012; April 16, 2012; March 28, 2012; March 20, 2012; March 7, 2012; February 22, 2012; February 8, 2012; January 25, 2012; January 3, 2012; November 16, 2011, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement